Similar articles

• Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

  Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, MacManus MP, Ryan G, Januszewicz H, Wolf M. Wirth A, et al. Am J Med. 2002 Mar;112(4):262-8. doi: 10.1016/s0002-9343(01)01117-2. Am J Med. 2002. PMID: 11893364
• FDG PET in the management of lymphoma: a clinical perspective.

  Hoskin PJ. Hoskin PJ. Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):449-51. doi: 10.1007/s00259-001-0755-4. Epub 2002 Feb 23. Eur J Nucl Med Mol Imaging. 2002. PMID: 11914880 No abstract available.
• The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment.

  Bar-Shalom R, Mor M, Yefremov N, Goldsmith SJ. Bar-Shalom R, et al. Semin Nucl Med. 2001 Jul;31(3):177-90. doi: 10.1053/snuc.2001.23519. Semin Nucl Med. 2001. PMID: 11430525 Review.
• Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

  Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Kostakoglu L, et al. Cancer. 2002 Feb 15;94(4):879-88. Cancer. 2002. PMID: 11920454 Clinical Trial.
• Positron emission tomography in the management of lymphomas: a summary.

  O'Doherty MJ, Hoskin PJ. O'Doherty MJ, et al. Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S128-30. doi: 10.1007/s00259-003-1170-9. Epub 2003 Apr 12. Eur J Nucl Med Mol Imaging. 2003. PMID: 12692689 Review. No abstract available.